Publications by authors named "Richard DelGizzi"
Article Synopsis
- The study investigates the potential benefits of inhibiting PCSK9, a protein, to improve the clearance of bacteria from the bloodstream and enhance outcomes in sepsis treatment.
- Researchers used genetic studies, a clinical trial analysis, and experimental animal models to explore the relationship between PCSK9 inhibition and sepsis mortality.
- Results showed a correlation in human cohorts between PCSK9 loss-of-function variants and lower sepsis mortality rates, while the clinical trial indicated low frequency of sepsis events among participants treated with alirocumab, a PCSK9 inhibitor.
Article Synopsis
- - Fibrodysplasia ossificans progressiva (FOP) is a rare condition that causes painful heterotopic ossification in connective tissues, leading to disability.
- - In the LUMINA-1 phase 2 trial, adults with FOP were given either garetosmab (an activin A-blocking antibody) or a placebo over two 28-week periods, focusing on safety and effects on HO lesions.
- - Although the primary efficacy endpoint was not met in the first period, garetosmab significantly reduced the development of new HO lesions in the second period compared to placebo, with ongoing investigations into its effectiveness.
We describe outcomes from the first-in-human study of garetosmab (a fully human monoclonal antibody that inhibits activin A) under development for the treatment of fibrodysplasia ossificans progressiva (FOP). In a double-blind, placebo-controlled phase 1 study, 40 healthy women of nonchildbearing potential were randomized to receive a single dose of intravenous garetosmab 0.3, 1, 3, or 10 mg/kg; subcutaneous garetosmab 300 mg; or placebo.
View Article and Find Full Text PDF